In recent years, Cinfa Biotech used its resources to advance B12019, a biosimilar copy of Amgen’s chemotherapy-induced neutropenia drug Neulasta, through clinical trials. B12019 and Neulasta are ...

As a result Neulasta was still Amgen’s second biggest selling drug last year, with the US accounting for nearly $3.9 billion in sales, with only $609 million coming from the rest of the world.

Over the years, we have created a portfolio of biosimilar products that are being marketed in several emerging markets. “The launch of our pegfilgrastim through our collaborator in the US in ...

"The addition of the Pegfilgrastim Injection to our BIOJAMP ® portfolio reinforces our commitment to providing Canadian patients with access to high-quality, cost-effective biosimilar medications," ...